NP201 – Parkinsons’ disease LAD™
Approximately 1.4 million people suffer from Parkinson’s disease in the United States, Europe, and Japan. By 2050, this number is expected to have doubled with the population of elderly (>65) individuals.
Parkinson’s disease is progressive, degenerative disease caused by the loss of dopaminergic neurons in the substantia nigra. The disease is characterized by motor neuron symptoms, such as tremor, bradykinesia, rigidity, gait dysfunction, and postural instability.
Parkinson’s patients are treated with a variety of therapeutics designed to replace lost dopaminergic function. Primary treatments include dopamine supplementation through dopamine agonists and/or carbidopa/levodopa. While these treatments are effective, dose complications, such as movement disorders, on/off fluctuations, and dyskinesias, are common. Many experts attribute these complications to variable drug levels resulting from frequent dosing or poor compliance with the prescribed dosing.
NP201 Parkinson’s disease LAD™ represents a potentially superior alternative to existing options by providing consistent drug levels over a prolonged period.
NP201 consists of a dopamine agonist formulated with LAD™ to provide effective relief for 1-3 months. By providing stable continuous drug delivery over an extended period, NP201 may significantly decrease the dose complications associated with current treatments. Furthermore, many researchers believe that continuous, stable stimulation of the dopamine receptors may slow the progression of the disease.
| Facts about Parkinson's |
- 1.4 million Parkinson’s patients worldwide
- 25% of treated patients experience drug complications
For more information about Parkinson's
|
